PRESS RELEASE published on 10/01/2024 at 06:55, 1 year 11 months ago Leclanché SA: Announces Extension of Publication Deadline for 2024 Interim Results Due to Ongoing Due Diligence with Pinnacle International Capital Leclanché extends publication deadline for 2024 interim results due to ongoing due diligence with Pinnacle International Capital, approved by SIX Exchange Regulation AG Due Diligence Leclanché Publication Deadline Pinnacle International Capital 2024 Interim Results
PRESS RELEASE published on 10/01/2024 at 06:50, 1 year 11 months ago Daldrup & Söhne AG doubles EBIT in H1 2024 Daldrup & Söhne AG doubles EBIT in H1 2024, achieving group total revenues increase and confirming raised forecast for 2024 Revenues EBIT Forecast Geothermal Energy Daldrup & Söhne AG
PRESS RELEASE published on 10/01/2024 at 06:20, 1 year 11 months ago SFS acquires leading Slovenian distribution partner in the construction industry SFS Group acquires EPRO D.O.O., a leading Slovenian distribution partner in the construction industry, strengthening its presence in the Adriatic region markets Acquisition Construction Industry Slovenia SFS Group EPRO D.O.O.
PRESS RELEASE published on 10/01/2024 at 02:05, 1 year 11 months ago High Grade Tarcoola Assays Confirm Additional Open Pit Gold Barton Gold confirms new high-grade open pit floor assays at Tarcoola Gold Project, supporting potential JORC Resource extensions. MD Scanlon anticipates additional gold ounces for 'Stage 1' operation Barton Gold Tarcoola Gold Project High-grade Assays JORC Resources Stage 1 Operation
PRESS RELEASE published on 10/01/2024 at 02:00, 1 year 11 months ago Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines Moderna Inc. and Cenra Healthcare enter joint agreement to co-promote mRNA respiratory vaccine portfolio in Taiwan, enhancing public health initiatives. Details undisclosed Moderna Taïwan MRNA Vaccine Cenra Healthcare Joint Agreement
PRESS RELEASE published on 10/01/2024 at 00:51, 1 year 11 months ago Inside Information: News release on accounts, results Valerio Therapeutics annonce ses résultats financiers du Premier Semestre 2024 et fait le point sur ses activités, y compris l'acquisition d'Emglev Therapeutics et le développement de la plateforme PlatONTM Résultats Financiers Biotechnologie Valerio Therapeutics Emglev Therapeutics Plateforme PlatONTM
PRESS RELEASE published on 10/01/2024 at 00:40, 1 year 11 months ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 23:00, 1 year 11 months ago Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities Biophytis publishes first-half financial results and business activities update, including launch of obesity program and licensing agreement with Blanver for Latin America, with a focus on key achievements and financial highlights Financial Results Biophytis Licensing Agreement Business Activities Obesity Program
PRESS RELEASE published on 09/30/2024 at 23:00, 1 year 11 months ago Biophytis publie ses comptes semestriels et fait le point sur ses activités Biophytis publie ses comptes semestriels et fait le point sur ses activités. La société présente ses résultats financiers pour le premier semestre 2024 et annonce les prochaines étapes de développement de ses programmes cliniques Biophytis Partenariat BIO101 Obésité Comptes Semestriels
REGULATED PRESS RELEASE published on 09/30/2024 at 23:00, 1 year 11 months ago Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities Biophytis publishes first-half financial results and updates on business activities, highlighting key achievements including launch of OBA program for obesity with BIO101 and exclusive licensing agreement with Blanver for Latin America Financial Results Biophytis Latin America BIO101 OBA Program
Published on 09/12/2026 at 02:35, 12 hours 29 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 16 hours 4 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 59 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 17 hours 39 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 22 hours 4 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 7 hours 34 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 49 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 54 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 19 hours 19 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 49 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 8 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 8 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 19 hours ago Availability of the 2026 Interim Financial Report